Role of the gut microbiome in chronic diseases: a narrative review

Abstract

The gut microbiome, i.e., the community of bacteria and other microorganisms living in the human gut, has been implicated both directly and indirectly (mediating the effects of diet) on human health [ 1 , 2 ]. The associations between gut microbiome composition and disease status have been widely reported, while recent studies have demonstrated a role for the gut microbiome in influencing remote organs, mucosal, and immune function [ 3 , 4 ]. Considerable effort is currently focused on understanding the natural history of microbiome development in humans in the context of health outcomes, in parallel with improving our knowledge of microbiome–host molecular interactions. These efforts ultimately aim to develop effective approaches to rehabilitate perturbed human microbial ecosystems as a means to restore health and prevent disease. This review details the role of the gut microbiome in chronic diseases (Fig. 1 ) and ways it can be modulated for the management or prevention of chronic conditions. Fig. 1: Schematic representation of the association of the composition of the gut microbiome and gut-derived metabolites with chronic diseases. The solid lines represent negative associations and the dashed lines represent positive associations of the disease phenotype with gut microbes and metabolites. Full size image Differences in gut microbiome composition and function have been associated with a variety of chronic diseases ranging from gastrointestinal inflammatory and metabolic conditions to neurological, cardiovascular, and respiratory illnesses. The aim of this narrative review is to describe the associations between gut microbiome composition and various types of chronic diseases and to discuss the links to habitual diet and dietary components (Table 1 ). Table 1 Summary of key findings outlining the role of the gut microbiome in chronic disease. Full size table Gut microbiome and autoimmune disease The pathogenesis of autoimmune diseases (AIDs) is not only attributed to genetic susceptibilities but also environmental factors, among which, a disturbed gut microbiota has attracted increasing attention. Compositional and functional changes of gut microbiota have been reported in various autoimmune diseases, and increasing evidence suggests that disturbed gut microbiota contributes to their immunopathogenesis. Rheumatoid arthritis (RA) Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory condition that manifests in joint damage. It was recently demonstrated that different environmental factors are involved in the development of both intestinal/oral dysbiosis and arthritis onset and outcome, among which the most relevant are diet, smoking, and infections [ 5 , 6 ]. The observation that germ-free mice are protected from development of experimental arthritis [ 7 ] suggests a possible role for the microbiome in the pathogenesis of this disease. The composition of the gut microbiota in RA patients free of therapy is severely altered compared to healthy controls. Chen et al. reported that compared with healthy controls, patients with RA show decreased gut microbial diversity, which correlates with autoantibody levels and disease duration [ 8 ]. In addition, at the compositional level, patients with RA show an increased abundance of Prevotella species, including Prevotella copri [ 8 , 9 ], and recent preclinical phase studies on RA patients in European countries were shown to harbor a high abundance of this species in the intestine, suggesting that dysbiosis precedes the development of arthritis [ 10 ]. In contrast, Faecalibacterium , which is generally recognized as a beneficial microbe, is decreased in RA patients. Furthermore, the relative abundance of Collinsella was found to be increased in RA patients [ 11 ]. Interestingly, inoculation of Collinsella into collagen-induced arthritis (CIA)-susceptible mice induces severe arthritis. In vitro experiments showed that Collinsella Aerofaciens increases gut permeability and induces IL-17A expression, a key cytokine involved in the pathogenesis of RA, suggesting that Collinsella is a candidate arthritogenic bacterium in the human intestine [ 11 ]. In summary , Prevotella copri [ 12 ] and Collinsella are the dominant gut microbiota in patients with early RA and may be involved in its pathogenesis. Recent links have been made between dietary intake of short-chain fatty acids (SCFAs) and autoimmune arthritis in mice, wherein SCFAs play an important role in the suppression of inflammation in RA [ 13 , 14 ]. Mice deficient for SCFA receptors showed exacerbated inflammation in modes of RA [ 14 ]. Butyrate, one of the most abundant SCFAs, acts as an endogenous histone deacetylase (HDAC) inhibitor and has been shown to decrease inflammation in animal models of RA and other inflammatory diseases [ 15 ]. A recent study has revealed a role for intestinal barrier function, and specifically for zonulin, a peptide that controls epithelial tight junction permeability, in regulating the onset of joint disease in mice with collagen-induced arthritis (CIA) and potentially also in patients with RA [ 16 ]. Increased levels of zonulin have been associated with leaky intestinal barrier, dysbiosis, and inflammation. Restoration of the intestinal barrier in the period before clinical arthritis, either by dietary supplementation with the SCFA butyrate or pharmacological agents such as a zonulin antagonist may help delay disease onset and reduce the severity of RA. Type 1 diabetes (T1D) In humans, intestinal microbiota alterations, including loss of bacterial diversity, preceded the onset of metabolic symptoms associated with T1D [ 17 ]. Previous studies have linked several facets of gut health with the onset of T1D in humans and animal models [ 18 , 19 , 20 ]. In animal models, antibiotic-induced dysbiosis, altered microbial lipid metabolism, and suppressed enteric Th17 and T-reg cell populations have led to increased incidence of T1DM-like disease in mice [ 21 ]. Various human-based studies have also reported altered intestinal microbiota in connection to T1D from several ethnic groups [ 17 20 , 22 , 23 , 24 ]. The common findings from these studies include increased numbers of Bacteroides species, and deficiency of bacteria that produce SCFAs [ 25 , 26 ] in cases of T1D. Specifically, the butyrate producer Faecalibacterium prausnitzii has been found to be decreased in abundance in children with diabetes-related autoantibodies [ 26 ]. In addition, increased intestinal permeability [ 22 ] and decreased microbial diversity [ 17 ] before T1D diagnosis have been reported. A multicenter case–control study of 783 children, showed that the microbiomes of healthy children contained more genes that were to the and the of SCFAs, but these were not associated with the abundance of clinical suggesting that microbial function composition was associated more with T1D [ ]. The effects of SCFAs in T1D have been in animal studies that have at models [ ]. mice in high bacterial of and butyrate were protected from T1D [ ] the effects of In animal models of autoimmune increased gut permeability precedes the development of and environmental factors that the permeability the incidence of the disease. Gut permeability to be an important in the between the intestinal microbiota and the development of T1D. gut permeability and inflammation have been linked to the development of T1D in humans [ 26 , ]. a chronic inflammatory is most in early The pathogenesis of has been attributed to immune as as [ ]. factors and have been shown to indirectly to pathogenesis of the disease of the gut microbiome [ ]. Previous studies have found that the gut microbiome in early is associated with of and of [ , ]. the association between gut microbiome diversity and development with studies an between gut diversity and the severity of [ , ]. The development of may be by the between gut microbiome the immune and the Specifically, in patients with the of , , and in the gut microbiome is in healthy controls, that of , , and Bacteroides is decreased [ , , , ]. The abundance of and in the intestine may be associated with inflammation [ ]. such as , are increased in with or healthy in with severe [ ]. Furthermore, from patients with showed decreased levels of butyrate and which have This is a of a dysbiosis in the SCFA producer prausnitzii that the of high butyrate and [ ]. It is that the compositional and in the gut microbiome are associated with the development of an of the gut The gut microbiome may to the and severity of and It is compositional changes in the gut microbiome the development of and the immune and the gut epithelial barrier, it to the development of The in in the several be by genetic factors and is to be to altered environmental associated with is the most important period which microbiota dysbiosis in the gut may to the development of respiratory diseases, as the gut microbiota has a on and to [ ]. A of have implicated environmental in increased for of these are to the gut microbiome, including [ ], [ ], and other environmental factors including [ ]. evidence for an between environmental the gut microbiome, and disease from an of experimental animal mice with was shown to gut microbial diversity, immune cell and to inflammation [ , ]. Furthermore, supplementation with SCFAs inflammation in these mice, with the attributed to decreased of such as and levels of [ ]. studies in humans have to be the most dominant in patients with compared with several studies [ ]. The is by potentially including that to the , , and [ ]. pathogenesis and severity are linked with The effects of the gut microbiota on are at by bacterial which may immune in of the The most metabolites with demonstrated in human inflammation are with high of butyrate and in at 1 of have and are to have between 3 and 6 [ ]. In addition, may the effects by SCFAs to associated receptors [ , ]. recent are studies that gut bacteria in humans are to produce other m

Full text

We don’t show the text of a retracted or withdrawn paper. The record stays, so citations to it can be checked.

Cited by papers we hold 4

• Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD) · 2024
  No notice
• Unveiling the therapeutic symphony of probiotics, prebiotics, and postbiotics in gut-immune harmony · 2024
  No notice
• Gut Microbiome–Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders · 2023
  No notice
• Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.